Heat Biologics, Inc. (HTBX) Scheduled to Post Earnings on Monday
Heat Biologics, Inc. (NASDAQ:HTBX) is scheduled to be posting its quarterly earnings results on Monday, October 30th. Analysts expect Heat Biologics to post earnings of ($0.09) per share for the quarter.
Heat Biologics, Inc. (NASDAQ HTBX) traded down 3.2943% during midday trading on Monday, hitting $0.6282. 71,602 shares of the company’s stock traded hands. Heat Biologics, Inc. has a 52 week low of $0.46 and a 52 week high of $3.35. The company’s market capitalization is $22.48 million. The company has a 50 day moving average of $0.64 and a 200-day moving average of $0.63.
An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. raised its holdings in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 661,388 shares of the biopharmaceutical company’s stock after acquiring an additional 70,290 shares during the quarter. Vanguard Group Inc. owned approximately 1.86% of Heat Biologics worth $403,000 at the end of the most recent quarter. 8.74% of the stock is owned by institutional investors.
Several equities analysts have weighed in on the company. Noble Financial reaffirmed a “buy” rating on shares of Heat Biologics in a research note on Tuesday, July 4th. ValuEngine cut Heat Biologics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th. Zacks Investment Research cut Heat Biologics from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Griffin Securities assumed coverage on Heat Biologics in a research note on Tuesday, September 12th. They set a “buy” rating and a $2.25 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Heat Biologics presently has an average rating of “Hold” and a consensus target price of $2.13.
ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/23/heat-biologics-inc-htbx-scheduled-to-post-earnings-on-monday.html.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.